Importance The assessment of the risk of venous thromboembolism (VTE) among
outpatients with cancer represents an unsolved topic. Current international guidelines …

Background The efficacy of risk model scores to predict venous thromboembolism (VTE) in
ambulatory cancer patients is under investigation, aiming to stratify on an individual risk …

Background Current risk assessment models (RAMs) for prediction of venous
thromboembolism (VTE) risk in the outpatient cancer population have shown poor predictive …

Cancer-associated venous thromboembolism (VTE) has major consequences for patients,
including morbidity and risk of mortality. However, there is substantial variation in risk …

Cancer patients with venous thromboembolism (VTE) are prone to poor prognoses. Thus,
we aimed to develop a nomogram to predict the risk of VTE in these patients. We …

The Khorana score is recommended for guiding primary venous thromboembolism (VTE)
prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains …

In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous
thromboembolism is not recommended. Several risk prediction scores to identify cancer …

Abstract Background The Khorana Score is a validated risk score for predicting 6‐month
incidence of cancer‐associated venous thromboembolism (CAT) among patients starting …

Venous thromboembolism (VTE) is common in cancer patients, and is associated with
significant morbidity and mortality. Several factors, including procoagulant agents secreted …

Treatment of patients with cancer-associated venous thromboembolism (VTE) remains a
major challenge. The modified Ottawa score is a clinical prediction rule evaluating the risk of …